Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT05071053 2025-08-22

CARMEN-GC01

Phase 2 Terminated

35 enrolled 14 charts

Phase 2 Active not recruiting

Adenocarcinoma Gastric

NCT02711553 2025-08-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

309 enrolled 22 charts

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT06038578 2025-08-03

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Phase 2 Recruiting

146 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT04394624 2025-06-06

CARMEN-LC04

Phase 2 Terminated

31 enrolled 22 charts

Non-small Cell Lung Cancer Metastatic

NCT05311176 2025-05-11

nextHERIZON

Phase 2 Terminated

7 enrolled 8 charts

Phase 2 Active not recruiting

Stomach Neoplasms

NCT05190445 2022-09-08

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

80 enrolled

HER2-positive Gastric Cancer

NCT01515306 2022-03-08

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

48 enrolled 17 charts

Other solid neoplasm

Malignant Solid Tumor

NCT01246986 2021-01-12

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

204 enrolled 27 charts

Carcinoma, Hepatocellular

NCT02443883 2020-06-29

A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

164 enrolled 13 charts

Stomach Neoplasms

NCT02514551 2020-06-17

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

245 enrolled 17 charts

Stomach Neoplasms

NCT02831491 2020-06-09

A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03704077 2020-05-19

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Phase 2 Withdrawn

Stomach Neoplasms

NCT01703091 2019-09-30

A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer

197 enrolled 12 charts

Non-small Cell Lung Cancer Metastatic

NCT01983878 2019-09-30

A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer

36 enrolled 21 charts

Stomach Neoplasms

NCT00721162 2019-09-26

Study of Ramucirumab in Ovarian Cancer

60 enrolled 14 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01160744 2019-09-13

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

280 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01282463 2019-09-09

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

148 enrolled 19 charts

Genitourinary

Carcinoma, Renal Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT01234402 2019-08-14

Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

153 enrolled 22 charts

Breast

Breast Neoplasms

NCT01111604 2019-08-06

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

158 enrolled 17 charts

Adenocarcinoma, Colonic Neoplasms, Rectal Neoplasms

NCT01634555 2019-02-26

A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI

29 enrolled 12 charts

Other solid neoplasm

Solid Tumors

NCT01427933 2017-02-06

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

141 enrolled 15 charts

Breast

Breast Neoplasms

NCT01017731 2015-06-10

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

68 enrolled 13 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT00735696 2014-12-29

A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer

41 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT00683475 2014-10-16

A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

138 enrolled 17 charts

Genitourinary

Prostatic Neoplasms

NCT01567163 2014-10-16

A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

22 enrolled 15 charts

Other solid neoplasm

Malignant Solid Tumor

NCT00627042 2014-10-08

Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

42 enrolled 19 charts

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

NCT01246960 2014-10-08

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

168 enrolled 16 charts

Esophageal Neoplasms, Neoplasms, Stomach Neoplasms

NCT00533702 2014-08-01

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

106 enrolled 15 charts

Dermatologic

Melanoma

NCT00515697 2014-06-18

A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma

39 enrolled 13 charts

Genitourinary

Carcinoma, Renal Cell

NCT00862784 2014-06-17

A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer

48 enrolled 15 charts